- Home
- SHMD vs TLSI Comparison
SHMD vs TLSI Comparison
Compare SHMD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- TLSI
- Stock Information
- Founded
- SHMD 1864
- TLSI 2010
- Country
- SHMD Germany
- TLSI United States
- Employees
- SHMD N/A
- TLSI N/A
- Industry
- SHMD
- TLSI Medical Specialities
- Sector
- SHMD
- TLSI Health Care
- Exchange
- SHMD Nasdaq
- TLSI Nasdaq
- Market Cap
- SHMD 171.9M
- TLSI 166.8M
- IPO Year
- SHMD N/A
- TLSI N/A
- Fundamental
- Price
- SHMD $3.82
- TLSI $5.14
- Analyst Decision
- SHMD
- TLSI Strong Buy
- Analyst Count
- SHMD 0
- TLSI 2
- Target Price
- SHMD N/A
- TLSI $14.00
- AVG Volume (30 Days)
- SHMD 23.1K
- TLSI 69.8K
- Earning Date
- SHMD 09-24-2024
- TLSI 08-14-2024
- Dividend Yield
- SHMD N/A
- TLSI N/A
- EPS Growth
- SHMD N/A
- TLSI N/A
- EPS
- SHMD N/A
- TLSI N/A
- Revenue
- SHMD N/A
- TLSI $24,736,000.00
- Revenue This Year
- SHMD N/A
- TLSI $61.24
- Revenue Next Year
- SHMD N/A
- TLSI $47.32
- P/E Ratio
- SHMD N/A
- TLSI N/A
- Revenue Growth
- SHMD 79.48
- TLSI 67.75
- 52 Week Low
- SHMD $2.69
- TLSI $3.32
- 52 Week High
- SHMD $6.13
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- TLSI 43.52
- Support Level
- SHMD N/A
- TLSI $4.80
- Resistance Level
- SHMD N/A
- TLSI $5.47
- Average True Range (ATR)
- SHMD 0.00
- TLSI 0.31
- MACD
- SHMD 0.00
- TLSI -0.01
- Stochastic Oscillator
- SHMD 0.00
- TLSI 34.69
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.